U
CLVS

UBS’s Clovis Oncology, Inc. CLVS Stock Holding History

UBS’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$100K Buy
2,200
+1,400
+175% +$58.5K ﹤0.01% 5999
2014
Q2 		$33K Sell
800
-600
-43% -$30.9K ﹤0.01% 7432
2014
Q1 		$97K Buy
+1,400
New +$103K ﹤0.01% 6014

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

UBS's CLVS Position: Q3 2014 in Review

UBS increased its Clovis Oncology, Inc. (CLVS) stake by 128% in Q3 2014, buying an estimated $2.86M and bringing the position to 121,579 shares worth $5.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1927.

UBS first reported a position in CLVS in Q2 2013 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold CLVS as of Q3 2014.

  • UBS held 121,579 shares of Clovis Oncology, Inc. worth $5.51M as of Q3 2014.
  • UBS bought 68,356 Clovis Oncology, Inc. shares in Q3 2014, an estimated $2.86M.
  • Clovis Oncology, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #1927 holding.
  • UBS first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 6 quarters since.
  • 138 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.